摘要
他参与了诺华制药多个重要产品,如格列卫、维格列汀的研发。让更多患者受益是他投入工作的原动力。其中,参与并推动新一代抗乙肝药物替比夫定在中国的临床开发及全球同步上市源于他那颗时刻与祖国一起跳动的心。如今,他率领他那年轻而富有激情的团队在上海一路前行。本期人物带您进入诺华(中国)生物医学研究有限公司药代动力学总监尹鹤群美丽的研发世界。
In the eyes of many people, drug research and development of tense and boring.While in the eyes of Dr.Yin He-qun, the director of pharmacokinetics in China Novartis Institutes for BioMedical Research Co., Ltd.(CNIBR),R&D is brave new world.Dr.Yin and his colleagues have taken part in R&D of multiple important products of Novartis, and to make more patients to benefit is the driving force of his work.Dr.Yin has taken part and promoted the simultaneous clinical trial of Telbivudine(Tyzeka) in China and the world.Dr.Yin is leading his young team full of passion all the way forward in Shanghai, faced with complex pharmaceutical R&D work, he is always positive and optimistic.
出处
《中国处方药》
2009年第8期50-53,共4页
Journal of China Prescription Drug
